A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

• Published in: The oncologist (Dayton, Ohio) Vol. 27; no. 9; pp. 718 - e694
• Main Authors: Schmidt, Keith T, Karzai, Fatima, Bilusic, Marijo, Cordes, Lisa M, Chau, Cindy H, Peer, Cody J, Wroblewski, Susan, Huitema, Alwin D R, Schellens, Jan H M, Gulley, James L, Dahut, William L, Figg, William D, Madan, Ravi A
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 02.09.2022
• Subjects: Antimitotic agents; Antineoplastic agents; Camptothecin; Camptothecin - therapeutic use; Chemotherapy, Combination; Clinical Trial Results; Cyclodextrins; Cystitis; Development and progression; Dosage and administration; Drug therapy; Health aspects; Humans; Male; Metastasis; Nanoparticles; Nitriles - therapeutic use; Patient compliance; Patient outcomes; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - pathology; Structure; Testing; Treatment Outcome; United States; Netherlands; metastatic castration-resistant prostate cancer (mCRPC); nanoparticle; NLG207; enzalutamide; noninfective cystitis
• ISSN: 1083-7159; 1549-490X; 1549-490X
• DOI: 10.1093/oncolo/oyac100

Abstract Background Despite the clinical efficacy of enzalutamide monotherapy in patients with advanced prostate cancer, therapeutic resistance and disease progression are inevitable. We proposed a study to evaluate NLG207, a nanoparticle-drug conjugate (NDC) of the potent topoisomerase I inhibitor camptothecin, in combination with enzalutamide, in patients with metastatic castration-resistant prostate cancer (mCRPC) following progression on enzalutamide. Methods This was a single-arm, optimal two-stage, phase II study to evaluate the efficacy of NLG207 in combination with enzalutamide in patients with mCRPC who received prior enzalutamide. A lead-in dose escalation evaluated the recommended phase 2 dose of NLG207 in combination with enzalutamide. Patients received NLG207 via IV infusion every 2 weeks and enzalutamide 160 mg orally once daily. Results Between March 2019 and June 2021, four patients were accrued to the lead-in dose escalation. Two of the four patients were evaluable and both experienced DLTs at the NLG207 12 mg/m2 dose level; one DLT was related to a dose delay for noninfective cystitis and myelosuppression, the other a grade 3 noninfective cystitis. Further evaluation of NLG207 in combination with enzalutamide was halted and the study was ultimately terminated. PSA declines from baseline were observed in two patients. Conclusion NLG207 12 mg/m2 in combination with enzalutamide was not well tolerated in patients with mCRPC following several lines of the standard of care therapy. ClinicalTrials.gov Identifier NCT03531827. This article reports the results of a trial that evaluated the efficacy of NLG207 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer who previously progressed on enzalutamide.